OIA
LCTX icon

OneDigital Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

OneDigital Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed – – 887
2019
Q2 		$0 Hold
100
– – ﹤0.01% 1237
2019
Q1 		$0 Hold
100
– – ﹤0.01% 1160
2018
Q4 		$0 Sell
100
-14
-12% -$21 ﹤0.01% 1211
2018
Q3 		$0 Hold
114
– – ﹤0.01% 1115
2018
Q2 		$0 Hold
114
– – ﹤0.01% 1343
2018
Q1 		$0 Hold
114
– – ﹤0.01% 1350
2017
Q4 		$0 Hold
114
– – ﹤0.01% 1258
2017
Q3 		$0 Hold
114
– – ﹤0.01% 1110
2017
Q2 		$0 Buy
+114
New +$318 ﹤0.01% 1229

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

OneDigital Investment Advisors's LCTX Position: Q3 2019 in Review

OneDigital Investment Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2019, closing a stake of 100 shares.

OneDigital Investment Advisors first reported a position in LCTX in Q2 2017 and held it in 9 quarters. The position peaked at $0 in Q2 2019. 96 funds tracked by Wall St. Rank hold LCTX as of Q3 2019.

  • OneDigital Investment Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2019 after selling out during the quarter.
  • OneDigital Investment Advisors sold 100 Lineage Cell Therapeutics shares in Q3 2019.
  • OneDigital Investment Advisors first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 9 quarters.
  • OneDigital Investment Advisors's Lineage Cell Therapeutics position peaked at $0 in Q2 2019.
  • 96 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2019.

Based on OneDigital Investment Advisors's 13F filing for Q3 2019, filed 8 Nov 2019.